tiprankstipranks
BioMarin Pharmaceutical Projects Strong Growth Through 2034
Company Announcements

BioMarin Pharmaceutical Projects Strong Growth Through 2034

Stay Ahead of the Market:

BioMarin Pharmaceutical ( (BMRN) ) just unveiled an announcement.

BioMarin Pharmaceutical Inc. has reiterated its strong financial outlook initially shared at its Investor Day, assuring stakeholders of robust growth prospects. The company expects to hit $4 billion in revenues by 2027, with Non-GAAP Operating Margins reaching 40% in 2026 and increasing thereafter. Additionally, they forecast over $1.25 billion in annual operating cash flow starting in 2027 and a mid-teen revenue growth rate annually through 2034. Treatments for skeletal conditions are also projected to become a significant revenue stream, surpassing $5 billion over time.

Learn more about BMRN stock on TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles